🇺🇸 FDA
Pipeline program

CD19 and CD22 targeted prime CAR- T cells

PBC026

Phase 2 mab active

Quick answer

CD19 and CD22 targeted prime CAR- T cells for B Cell Lymphoma is a Phase 2 program (mab) at PRECISION BIOSCIENCES INC with 1 ClinicalTrials.gov record(s).

Program details

Company
PRECISION BIOSCIENCES INC
Indication
B Cell Lymphoma
Phase
Phase 2
Modality
mab
Status
active

Clinical trials